SCHEMBL25905935

SCHEMBL25905935

CCN(C(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)C(C)Cc1ccc2c(c1)OCO2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
HPGD P15428 1/20 0.39
KLK7 P49862 2/20 0.39
KLK5 Q9Y337 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 1/20 0.37
CTSK P43235 1/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TAS1R3 Q7RTX0 2/20 0.37
TAS1R1 Q7RTX1 2/20 0.37
PARP1 P09874 1/20 0.37
PTPN1 P18031 1/20 0.37
MAPT P10636 1/20 0.37
TRPV1 Q8NER1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25314430 1.00 CA1 (0.40) CA1CA2HPGDKLK7KLK5
SCHEMBL25314424 1.00 CA1 (0.40) CA1CA2HPGDKLK7KLK5
SCHEMBL25906020 0.91 TAAR1 (0.38) HPGDSMN1; SMN2KDM4ETAS1R3TAS1R1
SCHEMBL24883838 0.90 CA1 (0.41) CA1CA2HPGDKLK7KLK5
SCHEMBL25906543 0.85 ACE (0.46) HPGDKLK5SMN1; SMN2CTSKALDH1A1
SCHEMBL25906022 0.85 ACE (0.46) HPGDKLK5SMN1; SMN2CTSKALDH1A1
SCHEMBL25906665 0.84 SMN1; SMN2 (0.42) HPGDSMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL25906451 0.83 SMN1; SMN2 (0.41) HPGDSMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL24883812 0.81 SMN1; SMN2 (0.39) HPGDSMN1; SMN2POLBKDM4EMAPT
SCHEMBL25309930 0.78 TAS1R3 (0.42) CA1CA2HPGDKLK7KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023137446-A1 PRODRUGS OF 3,4-METHYLENEDIOXY- N-ETHYL-AMPHETAMINE (MDEA) AND USES THEREOF TERRAN BIOSCIENCES INC. (US) 2023-07-20 WO disclosed